Literature DB >> 10671668

Induction of p53-dependent apoptosis in vivo by nedaplatin and ionizing radiation.

Y Nakamura1, M Hasegawa, K Hayakawa, M Matsuura, Y Suzuki, S Nasu, M Yamakawa, N Mitsuhashi, H Niibe.   

Abstract

p53 protein expression, apoptosis and growth delay induced by nedaplatin, a novel platinum compound, were investigated in vivo, and compared with those induced by ionizing radiation. A human ependymoblastoma with wild-type p53 was transplanted subcutaneously to the thighs of nude mice. The incidences of p53 protein-positive cells and apoptosis in tumors increased following exposure to ionizing radiation. In tumors treated with nedaplatin, they also increased, but the incidences of p53 protein-positive cells and apoptosis induced by 32 mg/kg nedaplatin, 1/2 LD50, were lower than those induced by 1 Gy irradiation. However, growth-delay assay showed no significant difference between the efficacy of 32 mg/kg nedaplatin and that of 1 Gy irradiation. These results suggest that the main antineoplastic activity caused by nedaplatin may be mediated through different mechanisms than those of the p53-dependent early apoptosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10671668     DOI: 10.3892/or.7.2.261

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Concurrent chemoradiotherapy with nedaplatin in patients with stage IIA to IVA cervical carcinoma.

Authors:  Toru Fujioka; Toshiaki Yasuoka; Masae Koizumi; Hiroki Tanaka; Hisashi Hashimoto; Motoo Nabeta; Koji Koizumi; Yuko Matsubara; Katsuyuki Hamada; Keiichi Matsubara; Tomihiro Katayama; Akihiro Nawa
Journal:  Mol Clin Oncol       Date:  2012-09-25

2.  Nedaplatin: a radiosensitizing agent for patients with cervical cancer.

Authors:  Seiji Mabuchi; Tadashi Kimura
Journal:  Chemother Res Pract       Date:  2010-09-21

3.  Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.

Authors:  Yijun Tian; Kongming Wu; Qian Liu; Na Han; Li Zhang; Qian Chu; Yuan Chen
Journal:  J Hematol Oncol       Date:  2016-09-06       Impact factor: 17.388

4.  Nedaplatin: a cisplatin derivative in cancer chemotherapy.

Authors:  Muneaki Shimada; Hiroaki Itamochi; Junzo Kigawa
Journal:  Cancer Manag Res       Date:  2013-05-08       Impact factor: 3.989

5.  Prospective phase II study of image-guided local boost using a real-time tumor-tracking radiotherapy (RTRT) system for locally advanced bladder cancer.

Authors:  Kentaro Nishioka; Shinichi Shimizu; Nobuo Shinohara; Yoichi M Ito; Takashige Abe; Satoru Maruyama; Rumiko Kinoshita; Keiichi Harada; Noboru Nishikawa; Naoki Miyamoto; Rikiya Onimaru; Hiroki Shirato
Journal:  Jpn J Clin Oncol       Date:  2013-12-02       Impact factor: 3.019

6.  Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers.

Authors:  Yijun Tian; Qian Liu; Kongju Wu; Qian Chu; Yuan Chen; Kongming Wu
Journal:  Oncotarget       Date:  2017-04-28

7.  The updated outcomes of bladder-preserving trimodal therapy using a real-time tumor-tracking radiotherapy system for patients with muscle-invasive bladder cancer.

Authors:  Haruka Miyata; Takahiro Osawa; Takashige Abe; Hiroshi Kikuchi; Ryuji Matsumoto; Satoru Maruyama; Kentaro Nishioka; Shinichi Shimizu; Takayuki Hashimoto; Hiroki Shirato; Nobuo Shinohara
Journal:  Jpn J Clin Oncol       Date:  2020-05-05       Impact factor: 3.019

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.